Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
Company profile
Ticker
PBM, PBMWW
Exchange
Website
CEO
Dr. Neil Maresky M.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
PBM stock data
Latest filings (excl ownership)
6-K
Share Purchase and Sale Agreement
20 Sep 24
6-K
Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq
13 Sep 24
6-K
Current report (foreign)
5 Sep 24
6-K
Current report (foreign)
30 Aug 24
424B3
Prospectus supplement
30 Aug 24
EFFECT
Notice of effectiveness
29 Aug 24
6-K
Current report (foreign)
20 Aug 24
F-1
Registration statement (foreign)
19 Aug 24
424B3
Prospectus supplement
19 Aug 24
EFFECT
Notice of effectiveness
16 Aug 24
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Jan 24 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Mar 24 | Jan 24 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q2 2024
45.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 28 |
Opened positions | 24 |
Closed positions | 0 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 69.76 mm |
Total shares | 7.61 mm |
Total puts | 0.00 |
Total calls | 108.00 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Harraden Circle Investments | 1.30 mm | $0.00 |
Cowen And | 1.17 mm | $12.28 mm |
Polar Asset Management Partners | 733.00 k | $7.70 mm |
MMCAP International Inc. SPC | 600.00 k | $6.30 mm |
Calamos Advisors | 500.00 k | $5.30 mm |
Cantor Fitzgerald, L. P. | 468.50 k | $4.92 mm |
Saba Capital Management | 297.85 k | $4.41 mm |
Aristeia Capital | 272.86 k | $4.04 mm |
Context Capital Management | 234.20 k | $2.46 mm |
Periscope Capital | 225.00 k | $2.36 mm |
News
Psyence Biomedical Enters Agreement With Psyence Group For Acquisition Of 11.13% Stake In Privately-held PsyLabs For About $1.1M
19 Sep 24
Psychedelic Biotech Psyence Grows Pipeline With Trials And Psilocybin Drug Developer Acquisition
16 Sep 24
Psyence Biomedical Announces Initiation Of First Trial Site In Australia For Phase IIb Study Of Nature Derived Psilocybin As Potential Treatment For Adjustment Disorder In Palliative Care
16 Sep 24
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
16 Sep 24
Psyence Biomed Launches First Trial Site In Australia For Phase IIb Psilocybin Study In Palliative Care
9 Sep 24
Press releases
Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs
19 Sep 24
Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
16 Sep 24
Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq
13 Sep 24
Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
9 Sep 24
Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
6 Sep 24